ABSTRACT
In recent years, there have been more and more reports about cystadenoma. Cystadenoma can occur in many parts of the body, and cystadenoma in different parts may show different clinical symptoms, however, some patients with cystadenoma have no symptoms. The vast majority of cystadenomas are benign lesions, but a small number of cystadenomas can be malignant. For example, a small number of ovarian cystadenomas and pancreatic cystadenomas may be malignant. This study reported a patient with small intestinal cystadenoma diagnosed by pathology. The patient's physical examination revealed a lesion in the left upper abdomen. He had only abdominal distension and no other discomfort. His laboratory examination results were basically normal, i.e. blood routine, urine routine, stool routine, liver function, kidney function, myocardial enzyme, tumor marker, etc. The patient underwent sectional small intestine resection and the pathological sample was analyzed. The histological findings of the resected intestinal sample were consistent with cystadenoma. Computed tomography scan of the abdomen was performed 4 months after the surgery. No recurrence of the tumor was found. The patient recovered in good condition. By consulting the literature, I found very few reports of small intestinal cystadenoma before, it was very rare. This article described the clinical manifestation, diagnosis and differential diagnosis, treatment and prognosis of a case of small intestinal cystadenoma, it suggested that cystadenoma can occur in the small intestine, other than the ovary, pancreas, liver, lung, thyroid, prostate, seminal vesicle, skin, etc. The cystadenoma in small intestine is easy to be mistaken with other tumors, such as small intestine stromal tumor, small intestine adenocarcinoma, small intestine lipoma, small intestine hemangiomas, etc., and it is difficult to fully confirm through imaging examinations, such as computed tomography and magnetic resonance imaging. Laparotomy and histopathological examination are necessary before definitive diagnosis. This disease can be treated by small bowel resection at the affected region and good prognosis can be achieved.
Subject(s)
Humans , Male , Cystadenoma , Intestinal Neoplasms , Intestine, Small , Neoplasm Recurrence, Local , Pancreatic Neoplasms , ProstateABSTRACT
Objective: To observe the clinical efficacy of modified Xiaofengsan and its effect on cytokines in persistent asthma patients with wind-asthma pattern. Method: The 120 eligible patients with chronic and persistent asthma were randomly divided into control group (60 cases) and treatment group (60 cases). Patients in control group received the budesonide/formoterol (160 μg/4.5 μg, 2 inhales/time, bid). Patients in treatment group additionally received the modified Xiaofengsan combined with budesonide/formoterol (160 μg/4.5 μg). The treatment course was 1 month in both groups. The clinical efficacy of the two groups was observed. Before and 3 months after treatment, asthma control test (ACT) and the average times of acute exacerbation in 6 months before and after treatment between two groups were observed; percentage of forced expiratory volume in first second and its predicted value (FEV1%), variety ratio of Peak expiratory flow (PEF), eosinophilic granulocyte (EOS) count in peripheral blood and the levels of interleukin-4(IL-4), interleukin-6(IL-6) and interleukin-13(IL-13) in serum were measured before and after treatment respectively. In addition, the safety of the two groups was evaluated. Result: The total effective rate of the treatment group was higher than that of the control group (P1% in treatment group were higher(PPConclusion: Modified Xiaofengsan combined with budesonide/formoterol could relieve symptoms of asthma, improve pulmonary function and lower the levels of IL-4, IL-6 and IL-13 in serum.
ABSTRACT
Objective:To explore the clinical efficacy of modified Jinshui Liujunjian combined with salmeterol/fluticasone on senile asthma on persistent stage and its effect on vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1) in serum. Method:The 100 cases of senile asthma who met inclusion criteria were selected and divided into two equal groups by random number table:the control group and the treatment group. Patients of the two groups were given oxygen therapy,phlegm reduction,infection control and salmeterol/fluticasone 50 μg·(500 μg)-1. Patients in control group were given sustained release capsule of theophylline in addition to the above therapy,while patients in treatment group were given modified Jinshui Liujunjian. The course of treatment was 8 weeks. The therapeutic effectiveness of traditional Chinese medicine (TCM) syndrome between two groups was observed. Asthma control test (ACT) scores at four different time points(before and after treatment,3, 6 months after treatment),pulmonary function,the levels of VEGF and TGF-β1 in serum before and after treatment between two groups were also observed. The pharmic safety during treatment was evaluated. Result:The total effective rate of treatment group was significantly higher than that of control group(PPβ1 in serum in treatment group were significantly lowered after treatment(P1%), and the percentage of forced expiratory volume in the first second and its forced vital capacity (FEV1/FVC) were significantly higher(PPConclusion:Modified Jinshui Liujunjian combined with Salmeterol/Fluticasone was more effective than Sustained release capsule of theophylline combined with Salmeterol/Fluticasone in improving the clinical efficacy and pulmonary function of senile asthma on the persistent stage. Its mechanism of action is probable correlated with the reduction of levels of VEGF and TGF-β1 in serum.
ABSTRACT
BACKGROUND: Palatal rugae have unique properties in each individual, which can be applied in the studies on dental forensics. OBJECTIVE: To measure the parameters of palatal rugae in Uygur populations, so as to provide a new idea for its recognition of dental forensics. METHODS: Palate rugae models from 268 Uygur adults aged 19-25 years were collected. The palatal rugae pattern code units (PRPCU) were obtained according to the morphological parameters of palatal rugae such as shape, length and position distribution, and then the PRPCU was converted into a two-dimensional code using online barcode generator to analyze the specificity of palate rugae. RESULTS AND CONCLUSION: The palate rugae in 268 palatal rugae models were different, and the most commonly seen shape was straight (2.76±1.69), followed by curve (1.74±1.35), wavy (1.06±0.90) and circular (0.09±0.351). The most common length classification was the primary rugae (6.17±1.75), followed by secondary rugae (0.70±0.97), and fragmentary rugae (0.33±0.682). The distribution of palatal rugae shape and length was significantly different among Uygur individuals (P < 0.001). Only the straight shape showed significant difference between male and female in Uygur populations (P < 0.05). That is to say, different individuals possess different palate rugae, so a digital record of palatal rugae can be used for personal identification.